Furthermore, acetylated-Tau (lysine 174) level increased in the early stage of AD, while high levels of 274 and 281 lysine residues of the acetylated-Tau were recorded in the brains of AD patients in the late stagy of AD (Tracy and Gan 2017). The gene discussed is MAPT; the disease is Alzheimer disease.